Civeo (CVEO) At $3.88 Forms Top; Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Shorts Increased By 2.51%

Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) Logo

Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) had an increase of 2.51% in short interest. AMPE’s SI was 9.09 million shares in June as released by FINRA. Its up 2.51% from 8.86 million shares previously. With 981,000 avg volume, 9 days are for Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE)’s short sellers to cover AMPE’s short positions. The SI to Ampio Pharmaceuticals Inc’s float is 14.07%. The stock increased 2.66% or $0.05 during the last trading session, reaching $1.93. About 321,051 shares traded. Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) has risen 155.77% since June 12, 2017 and is uptrending. It has outperformed by 143.20% the S&P500. Some Historical AMPE News: ; 15/03/2018 – Ampio Pharma: Audited Fincl Statements Contained Going Concern Explanatory Paragraph; 13/04/2018 – Ampio Closes Below 50-Day Moving Average: Technicals; 06/03/2018 Ampio Hosting Conference Call, Wednesday, March 7, 5:00 pm EST; 26/03/2018 – AMPIO PHARMACEUTICALS INC – PRIMARY ENDPOINT WAS CHANGE IN WOMAC A PAIN BETWEEN BASELINE AND WEEK 20; 14/05/2018 – AMPIO PROVIDES CORPORATE UPDATE; 29/05/2018 – AMPIO PHARMACEUTICALS INC – AWARDED US PATENT TITLED “TREATMENT OF JOINT CONDITIONS” THAT PROVIDES METHOD PROTECTION, UNTIL YEAR 2035; 03/04/2018 – Ampio Updates Regulatory and Clinical Activities; 22/05/2018 – Ampio Updates Scientific presentations and publications on Ampion™; 26/03/2018 – Evidence for Delay of Total Knee Replacement (TKR) for Patients with Severe Osteoarthritis of the Knee Receiving Three Intra-ar; 26/03/2018 – EVIDENCE FOR DELAY OF TOTAL KNEE REPLACEMENT (TKR) FOR PATIENTS WITH SEVERE OSTEOARTHRITIS OF THE KNEE RECEIVING THREE INTRA-ARTICULAR (IA) AMPION™ INJECTIONS

Civeo Corporation (CVEO) formed multiple top with $4.22 target or 9.00% above today’s $3.88 share price. Civeo Corporation (CVEO) has $649.84 million valuation. The stock decreased 2.15% or $0.085 during the last trading session, reaching $3.875. About 314,856 shares traded. Civeo Corporation (NYSE:CVEO) has risen 68.57% since June 12, 2017 and is uptrending. It has outperformed by 56.00% the S&P500. Some Historical CVEO News: ; 27/04/2018 – Civeo 1Q Loss/Shr 42c; 27/04/2018 – Civeo 1Q Rev $101.5M; 09/04/2018 – Lance Torgerson, Affiliates Report Stake In Civeo; 30/05/2018 – Civeo Closes Above 50-Day Moving Average: Technicals; 27/04/2018 – CIVEO – FOR 2018, CO EXPECTS EBITDA OF $93 MLN TO $100 MLN, INCLUSIVE OF OPERATIONS ACQUIRED IN NORALTA AND LOUISIANA ACQUISITIONS; 27/04/2018 – Civeo Sees 2Q EBIT $28M-EBIT $30M; 27/04/2018 – Civeo Sees 2018 EBIT $93M-EBIT $100M; 09/04/2018 – LANCE TORGERSON REPORTS 24.8 PCT STAKE IN CIVEO CORP AS OF APRIL 2 – SEC FILING; 28/03/2018 – Civeo Shareholders Approve Share Issuance Proposal For Pending Acquisition Of Noralta Lodge; 02/04/2018 – CIVEO CORP – EXTENDS CREDIT FACILITY’S MATURITY DATE OF OBLIGATIONS THEREUNDER TO NOV 30, 2020

Investors sentiment increased to 2.79 in Q1 2018. Its up 0.49, from 2.3 in 2017Q4. It improved, as 9 investors sold Ampio Pharmaceuticals, Inc. shares while 5 reduced holdings. 19 funds opened positions while 20 raised stakes. 11.36 million shares or 36.31% more from 8.34 million shares in 2017Q4 were reported. Jfs Wealth Llc invested in 0.02% or 23,150 shares. Wealthtrust Axiom Ltd Liability has invested 0.01% in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE). United Cap Financial Advisers Limited Liability Co accumulated 0% or 20,303 shares. Oppenheimer Inc stated it has 0% of its portfolio in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE). Bluecrest Mgmt Limited holds 0.03% in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) or 311,257 shares. Two Sigma Securities Ltd Company, New York-based fund reported 10,518 shares. Cypress Cap Limited Liability Corporation (Wy) stated it has 166,400 shares. Deutsche Comml Bank Ag holds 0% or 446,175 shares in its portfolio. Manufacturers Life Insurance The stated it has 0% of its portfolio in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE). Raymond James Financial Advisors Inc has invested 0% of its portfolio in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE). Moreover, Northern Tru Corporation has 0% invested in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) for 139,992 shares. Geode Cap Management holds 0% in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) or 487,410 shares. Balyasny Asset Mgmt Limited Liability Company, a Illinois-based fund reported 45,200 shares. Susquehanna Intll Llp holds 214,183 shares or 0% of its portfolio. Weiss Asset Mgmt Lp holds 38,026 shares or 0.01% of its portfolio.

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company has market cap of $166.60 million. The firm is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. It currently has negative earnings. The Company’s product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema.

Among 7 analysts covering Civeo Corporation (NYSE:CVEO), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Civeo Corporation has $5 highest and $2 lowest target. $4.08’s average target is 5.29% above currents $3.875 stock price. Civeo Corporation had 15 analyst reports since September 2, 2015 according to SRatingsIntel. RBC Capital Markets maintained Civeo Corporation (NYSE:CVEO) on Thursday, December 21 with “Hold” rating. RBC Capital Markets maintained the shares of CVEO in report on Friday, June 23 with “Hold” rating. Scotia Capital maintained the stock with “Buy” rating in Thursday, March 23 report. The stock has “Sector Outperform” rating by Howard Weil on Tuesday, September 15. The firm earned “Hold” rating on Friday, October 6 by RBC Capital Markets. The firm has “Buy” rating given on Thursday, March 23 by Craig Hallum. RBC Capital Markets maintained Civeo Corporation (NYSE:CVEO) on Thursday, March 1 with “Hold” rating. The stock of Civeo Corporation (NYSE:CVEO) earned “Sector Outperform” rating by Howard Weil on Friday, May 6. The company was upgraded on Wednesday, September 2 by Sterne Agee CRT. The stock of Civeo Corporation (NYSE:CVEO) earned “Hold” rating by RBC Capital Markets on Friday, September 1.

Civeo Corporation (NYSE:CVEO) Ratings Chart